Human papillomavirus, L1 protein virus like particles
Highest phase reached
Approved
Drug type
Vaccine component
First approval year
2006
- First approval year
- 2006
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Vaccine component
- Drug name
- Human papillomavirus, L1 protein virus like particles
- cervarix
- Cervarix
- gardasil
- Gardasil
- gardasil 9
- Gardasil 9
- silgard
- Silgard
- 9 valent human papillomavirus vaccine gardasil 9 1 dose
- 9-valent human papillomavirus vaccine (Gardasil 9) - 1 dose
- 9-valent human papillomavirus vaccine (Gardasil 9) - 2 doses
- 9-valent human papillomavirus vaccine (Gardasil 9) - 3 doses
- cervarix
- Cervarix
- CERVARIX
- Cervarix.
- Cervarix®
- Cervarix™
- Gardasil
- GARDASIL
- Gardasil ® (Merck & Co. Inc)
- Gardasil ® 9
- GARDASIL ®9
- Gardasil 9
- Gardasil 9 Suspension for Injection
- Gardasil 9®
- Gardasil-9
- Gardasil®
- GARDASIL®
- GARDASIL® 9
- Gardasil®9
- GARDASIL®9
- GARDASIL®9 (G9)
And 13 more, listed on the interactive page.
- ChEMBL ID
- CHEMBL6068359
- First in class
- No
- Orphan designation
- No
- Drug name stem
- vir-; -vir-
- Condition
- Papillomavirus Infections
- Highest recorded phase
- 4
- Condition identifier
- EFO:0001668
- Subject identifier
- D030361
- Condition
- Vaccination
- Highest recorded phase
- 4
- Condition identifier
- EFO:0004292
- Subject identifier
- D014611
- Condition identifier
- EFO_0001668
- Condition identifier
- MONDO_0000935
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0001209
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0001402
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0001528
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002974
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002974
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0003199
- Condition identifier
- MONDO_0005161
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005173
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005233
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005647
- Condition identifier
- MONDO_0007915
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0022394
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0022394
- Highest recorded phase
- 3
- Event
- abdominal pain
- Reports
- 10
- Reporting signal score
- 11.7359
- Event
- abdominal pain lower
- Reports
- 4
- Reporting signal score
- 9.60133
- Event
- acne conglobata
- Reports
- 3
- Reporting signal score
- 21.6793
- Event
- ankyloglossia congenital
- Reports
- 2
- Reporting signal score
- 10.6771
- Event
- anxiety
- Reports
- 7
- Reporting signal score
- 7.65353
- Event
- autoimmune disorder
- Reports
- 2
- Reporting signal score
- 6.24164
- Event
- autoimmune enteropathy
- Reports
- 1
- Reporting signal score
- 6.90559
- Event
- bacterial disease carrier
- Reports
- 2
- Reporting signal score
- 10.5373
- Event
- blood creatinine decreased
- Reports
- 2
- Reporting signal score
- 7.17006
- Event
- bone cyst
- Reports
- 2
- Reporting signal score
- 9.25341
- Event
- cervical dysplasia
- Reports
- 2
- Reporting signal score
- 7.44772
- Event
- cervix inflammation
- Reports
- 1
- Reporting signal score
- 6.37522
- Event
- chronic gastritis
- Reports
- 2
- Reporting signal score
- 8.24766
- Event
- coagulation time shortened
- Reports
- 2
- Reporting signal score
- 11.0022
- Event
- colitis microscopic
- Reports
- 3
- Reporting signal score
- 10.7781
- Event
- congenital ectodermal dysplasia
- Reports
- 1
- Reporting signal score
- 7.59856
- Event
- disturbance in attention
- Reports
- 6
- Reporting signal score
- 14.125
- Event
- episiotomy
- Reports
- 1
- Reporting signal score
- 7.59856
- Event
- facial paresis
- Reports
- 2
- Reporting signal score
- 6.53889
- Event
- fatigue
- Reports
- 12
- Reporting signal score
- 6.70657
- Event
- fibroadenoma of breast
- Reports
- 2
- Reporting signal score
- 11.0766
- Event
- food intolerance
- Reports
- 2
- Reporting signal score
- 7.89963
- Event
- general physical health deterioration
- Reports
- 6
- Reporting signal score
- 9.89292
- Event
- headache
- Reports
- 13
- Reporting signal score
- 10.0163
- Event
- hepatic necrosis
- Reports
- 2
- Reporting signal score
- 6.84468
And 42 more, listed on the interactive page.
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (217)
- 4-valent HPV Vaccine to Treat Recurrent Respiratory Papillomatosis in Children
- 9-valent HPV Vaccine in Postpartum Women
- A Clinical Study of V540A in Healthy Female Participants (V540A-005)
- A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17
- A Cohort Study to Assess Sustained Immunogenicity to qHPV Vaccine Among HIV-infected Girls and Boys Age 9-14 Years
- A Controlled Trial to Assess the Immunogenicity of a Proposed Paediatric Dosing Schedule of Human Papillomavirus Vaccine
- A Dose Reduction Immunobridging and Safety Study of Two HPV Vaccines in Tanzanian Girls
- A Model for Implementation of Cervical Cancer Screening and HPV Vaccination the Emergency Department: a Pilot Study
- A Phase I Safty and Immunogenicity Study of SCT1000 in Healthy Women Aged 18 to 45 Years
- A Phase I Study of Quadrivalent HPV Recombinant Vaccine
- A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents, and Young Adults
- A Phase II Study of SCT1000 in Healthy Women Aged 18 to 45 Years
- A Single Centre Study to Evaluate the Safety and Immunogenicity of the Human Papillomavirus Vaccine (GSK-580299) in Chinese Females
- A Study of Reduced Dosing of the Nonavalent HPV Vaccine in Women Living With HIV
- A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine
- A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age
- A Study to Assess the Reduction of Human Papillomavirus (HPV) Viral Infectivity and Transmission in HPV-Positive Women After Vaccination With 9vHPV (RIFT-HPV)
- A Study to Assess the Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (Cervarix) in Healthy Female Filipino Subjects Vaccinated According to the Prescribing Information From the Age of 10 Years Onwards.
- A Study to Compare Immune Response of V503 to Gardasil in 16- to 26-year-old Men (V503-020)
- A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine/Cervarix TM Vaccine in Healthy Females Aged 15-25 Years
Approved for (1)
In development for (4)
- Cervical cancer Phase 3
- Cervical intraepithelial neoplasia Phase 3
- Larynx squamous papilloma Phase 3
- Systemic lupus erythematosus Phase 1